Bimiralisib
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
Catalog Number | T2265 |
Alternative Name(s) | PI3K-IN-2 , 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine , PQR309 |
Research Area | Others|||PI3K/Akt/mTOR signaling|||MAPK |
Molecular Formula | C17H20F3N7O2 |
CAS# | 1225037-39-7 |
SMILES | C1COCCN1c1nc(c2cnc(cc2C(F)(F)F)N)nc(n1)N1CCOCC1 |
Size | 100 mg |
Supplier Page | https://www.targetmol.com/compound/Bimiralisib |
Additional Information | https://www.targetmol.com/datasheet/T2265 |